secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2021-10-20T23:59:59+00:00
Accession:  0000950142-21-003244
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics appoints Deepa Prasad as President and CEO; Holcombe retires
-----------------------------------------------------------------------------

- Stephen Holcombe retired as CEO effective Oct 19, 2021; will serve as Strategic Advisor for one year, receiving $450k/yr severance through Dec 2022.
- Deepa Prasad appointed President & CEO; base salary $650k, 100% bonus, options for 2,498,635 shares at $1.47.
- Prasad brings 20+ years healthcare experience; was Managing Director at WestRiver Group, led investments in DSGN, Ginger, Curai.
- Company to launch Phase 3 pivotal studies for TTP399, a Type 1 diabetes treatment with FDA Breakthrough Therapy Designation.
- TTP399 Phase 2 showed significant HbA1c improvement and 40% reduction in symptomatic hypoglycemia vs placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000095014221003244/0000950142-21-003244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000095014221003244/eh210193502_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-21-003244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer